CD44 and lymphoma: Interestingly, Sagiv-Barfi et al. reported that PD-L1 inhibition combined with ibrutinib treatment (in A20 lymphoma cell line) led to increased frequency of IFN-gamma-producing CD44+ central memory T cells [19].